Abstract |
Angioimmunoblastic lymphadenopathy with dysproteinemia (AILD) or lymphogranulomatosis X is a lymphoproliferative disorder with a histological picture resembling that of reactive lesions but with frequent cytogenetic and molecular abnormalities characteristic of malignant T cell lymphoma. Clinically, the disease runs a fatal course in the majority of patients although occasional spontaneous remissions have been observed. Median survival approaches only 1 year even with the most effective treatment protocols implemented so far. Fewer than 20% of patients survive 5 years after diagnosis and cure seems exceedingly rare. High-dose chemotherapy (HDCT) followed by autologous bone marrow transplantation (ABMT) represents a promising new treatment modality for patients with advanced lymphoma conceivably including AILD. We report the first patient with relapsed AILD successfully treated by HDCT and ABMT. This 21-year-old male is alive and free of disease 27 months after ABMT with a Karnofsky score of 100%.
|
Authors | N Schmitz, E Prange, T Haferlach, H Griesser, R Sonnen, B Schlegelberger, S Claus, H Löffler |
Journal | Bone marrow transplantation
(Bone Marrow Transplant)
Vol. 8
Issue 6
Pg. 503-6
(Dec 1991)
ISSN: 0268-3369 [Print] England |
PMID | 1790431
(Publication Type: Case Reports, Journal Article, Research Support, Non-U.S. Gov't)
|
Chemical References |
- Antineoplastic Agents
- Vincristine
- Doxorubicin
- Cyclophosphamide
- Prednisone
|
Topics |
- Adult
- Antineoplastic Agents
(therapeutic use)
- Antineoplastic Combined Chemotherapy Protocols
(therapeutic use)
- Blood Protein Disorders
(complications, metabolism)
- Bone Marrow Transplantation
- Combined Modality Therapy
- Cyclophosphamide
(administration & dosage)
- Dose-Response Relationship, Drug
- Doxorubicin
(administration & dosage)
- Humans
- Immunoblastic Lymphadenopathy
(complications, metabolism, therapy)
- Male
- Prednisone
(administration & dosage)
- Recurrence
- Transplantation, Autologous
- Vincristine
(administration & dosage)
|